Navigation Links
Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
Date:3/13/2008

or the

cohort dosed least frequently.

-- As expected in this short term study, the levels of relevant markers

of Gaucher disease including platelet counts, hemoglobin levels,

glucocerebroside (substrate) levels, chitotriosidase activity and

pulmonary activation-related chemokine (PARC) levels were maintained.

"These data give us great confidence in moving our Gaucher program forward," said John F. Crowley, President and CEO of Amicus Therapeutics. "In addition to a 6-month Phase 2 study in individuals naive to ERT, which is currently underway, we plan to initiate a longer-term study in individuals switching from enzyme replacement therapy to Plicera in the second half of this year."

As of November 2007, Plicera is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases.

About Gaucher Disease

Gaucher disease is a lysosomal storage disorder caused by inherited genetic mutations in the GBA gene, which result in deficient activity of the enzyme acid beta-glucosidase, also known as glucocerebrosidase (GCase). Deficient GCase activity leads to lysosomal accumulation of glucocerebroside inside certain cells, which is believed to cause the various symptoms of Gaucher disease, including an enlarged liver and spleen, abnormally low levels of red blood cells and platelets and skeletal complications. In some cases there is significant impairment of the central nervous system.

Gaucher disease is estimated to affect approximately 10,000 people in the developed world. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in Plicera in the United States and the European Commission has designated Plicera as an orphan medicinal product in the European Union.

About Amicus Therapeutics

Amicus Therapeutics is a biopharm
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Mass. Using a bio-mimicking analog of one ... grass, an international research team led by Alejandro ... taken a major step in developing long-sought polymer ... electricity for use in electronic devices. , ... Amherst and others at Stanford University and Dresden ...
(Date:9/30/2014)... , Sept. 30, 2014 Nematicide is ... nematodes. Nematodes are microscopic parasitic roundworms, found in ... inside other plants and animals. Nematicides have tended ... other properties promoting migration through the soil. A ... 1,000 plant-parasitic nematodes. With more than 10,000 species ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  RegeneRx ... today announced that it has received a Canadian ... by Actin-Sequestering Peptides.  This patent includes claims using ... numerous other actin-sequestering peptides for these purposes.  The ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Separation (EWS), the high-speed, chemical-free process to clean up ... letter to shareholders, CEO Riggs Eckelberry reported on the ... West Texas, at a site provided by partner ... ramped up to 1000 barrels per day (bpd) and ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2
... from McGill,s Physics Department and Mike Lilly from Sandia ... electronic circuits. It is formed by two wires separated ... This discovery, published in the journal Nature Nanotechnology ... and power of the ever smaller integrated circuits of ...
... LONDON, December 7, 2011 Silence Therapeutics plc ... ( RNAi ) therapeutics company, announces a positive outcome from the ... (EPO) over opposition to Silence,s granted European Patent EP 1 536 ... The granted patent refers to the gene target PKN3, protein ...
... 2011  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... , 2.875% Convertible Senior Notes due February 15, 2015 ... $1,000 principal amount or approximately $6.44 per share, effective December ... May 1, 2015 (May 2015 Notes) is 135.9849 shares of ...
Cached Biology Technology:Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 2Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 3Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office 4PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes 2
(Date:9/30/2014)... think of nature as something that we enjoy when we ... Or do we think of ourselves as a part of ... what about a house? , The answers to these ... our actions, our speech and in cultural artifacts. , A ... Washington, the American Indian Center of Chicago and the Menominee ...
(Date:9/30/2014)... LA JOLLAJoseph Ecker, a Salk professor and Howard ... staff scientist, have been named recipients in the ... of Health (NIH) through the BRAIN (Brain Research ... in neuroscience. The grant, announced September 30, provides ... Salk scientists over three years. , The BRAIN ...
(Date:9/30/2014)... is available in German . ... the most expensive foods in the world. Because they grow ... But the distinctive smell of truffles is not only of ... under the direction of the Goethe University Frankfurt have discovered ... soil bacteria which are trapped inside truffle fruiting bodies. , ...
Breaking Biology News(10 mins):The cultural side of science communication 2Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2
... A new discovery in stem cell research may mean big ... Ph.D., and a research team at the University of Kentucky ... journal. , The researchers genetically mapped a stem cell ... effort, carried the investigation all the way through to the ...
... at the University of Missouri-Columbia, recently found fossil evidence ... present-day Peru that showed people were eating domesticated chili ... chili peppers one of the oldest domesticated food sources ... the Feb. 15 edition of the journal Science. , ...
... When man made his way out of Africa some ... not alone: He was accompanied by the bacterium Helicobacter ... man and the bacterium spread throughout the entire world. ... of scientists led by Mark Achtman from the Max ...
Cached Biology News:Researchers first to map gene that regulates adult stem cell growth 2Researchers find 6,000-year-old fossil evidence 2Out of Africa -- Bacteria, as well 2
... a derivative of the pAcHLT-A Vector (Cat. No. ... (BFP), followed by a 6xHis tag and a ... BFP-6xHis fusion proteins when cloned into one of ... Sac I, Not I, Pst I, Kpn I, ...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
... pLivSelect is a direct antibiotic-based selection ... solely on colony survival, eliminating the need ... inexpensive process provides close to 100% accuracy ... ideal platform for robot colony picking. This ...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Biology Products: